VIDEO: OlympiA trial shows olaparib’s benefits for patients with BRCA mutations ‘persist’
Click Here to Manage Email Alerts
SAN ANTONIO — In this video, Halle Moore, MD, discusses the long-term results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.
The randomized multicenter phase 3 study observed patients with germline BRCA1 or BRCA2 pathogenic variants and high-risk HER2-negative breast cancer treated with adjuvant olaparib (Lynparza; AstraZeneca, Merck) after neoadjuvant chemotherapy treatment.
“The benefits of adjuvant olaparib in patients with BRCA mutations, treated in the adjuvant setting, continued to persist,” Moore, medical oncologist and director of breast oncology program at Cleveland Clinic, said. “And I was also very pleased to see that there did not appear to be an increased risk [for] myelodysplasia or acute leukemia, which is a potential side effect of olaparib that people were concerned about.”
Reference:
- Garber JE, et al. Abstract GS1-09. Presented at: San Antonio Breast Cancer Symposium; December 10-13, 2024; San Antonio.
Collapse
Healio Interviews
Click Here to Manage Email Alerts